545 related articles for article (PubMed ID: 17846007)
21. Bevacizumab in combination with chemotherapy: first-line treatment of patients with metastatic colorectal cancer.
Hochster HS
Semin Oncol; 2006 Oct; 33(5 Suppl 10):S8-14. PubMed ID: 17145525
[TBL] [Abstract][Full Text] [Related]
22. New systemic frontline treatment for metastatic colorectal carcinoma.
Braun AH; Achterrath W; Wilke H; Vanhoefer U; Harstrick A; Preusser P
Cancer; 2004 Apr; 100(8):1558-77. PubMed ID: 15073842
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan.
Shiroiwa T; Fukuda T; Tsutani K
Clin Ther; 2007 Oct; 29(10):2256-67. PubMed ID: 18042483
[TBL] [Abstract][Full Text] [Related]
24. New oxaliplatin-based combinations in the treatment of colorectal cancer.
Cassidy J; Hochster H
Colorectal Dis; 2003 Nov; 5 Suppl 3():1-9. PubMed ID: 23573555
[TBL] [Abstract][Full Text] [Related]
25. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer.
Kabbinavar FF; Hambleton J; Mass RD; Hurwitz HI; Bergsland E; Sarkar S
J Clin Oncol; 2005 Jun; 23(16):3706-12. PubMed ID: 15867200
[TBL] [Abstract][Full Text] [Related]
26. Angiogenesis inhibitors in the treatment of colorectal cancer.
Iqbal S; Lenz HJ
Semin Oncol; 2004 Dec; 31(6 Suppl 17):10-6. PubMed ID: 15696025
[TBL] [Abstract][Full Text] [Related]
27. Bevacizumab: new drug. Metastatic colorectal cancer: good in theory, not in practice.
Prescrire Int; 2006 Jun; 15(83):94-7. PubMed ID: 16764097
[TBL] [Abstract][Full Text] [Related]
28. Chemotherapy of metastatic colorectal cancer.
Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
[TBL] [Abstract][Full Text] [Related]
29. Angiogenesis inhibition with bevacizumab and the surgical management of colorectal cancer.
Thornton AD; Ravn P; Winslet M; Chester K
Br J Surg; 2006 Dec; 93(12):1456-63. PubMed ID: 17115389
[TBL] [Abstract][Full Text] [Related]
30. [Are antiangiogenic antibodies universal for solid tumor?].
Ray-Coquard I; Bachelot T; Saba C; Confavreux C; Brantus JF; Rustam F; Ghesquière H; Sebban C; Biron P; Guastalla JP; Blay JY
Bull Cancer; 2007 Jul; 94 Spec No():S191-6. PubMed ID: 17846004
[TBL] [Abstract][Full Text] [Related]
31. Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer.
Krämer I; Lipp HP
J Clin Pharm Ther; 2007 Feb; 32(1):1-14. PubMed ID: 17286784
[TBL] [Abstract][Full Text] [Related]
32. Current role of bevacizumab in colorectal cancer.
Saltz L
Clin Adv Hematol Oncol; 2009 Jun; 7(6):375-6. PubMed ID: 19606071
[No Abstract] [Full Text] [Related]
33. Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer.
Whyte S; Pandor A; Stevenson M; Rees A
Health Technol Assess; 2010 Oct; 14(Suppl. 2):47-53. PubMed ID: 21047491
[TBL] [Abstract][Full Text] [Related]
34. New approaches in angiogenic targeting for colorectal cancer.
Prat A; Casado E; Cortés J
World J Gastroenterol; 2007 Nov; 13(44):5857-66. PubMed ID: 17990351
[TBL] [Abstract][Full Text] [Related]
35. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.
Grothey A; Ellis LM
Cancer J; 2008; 14(3):170-7. PubMed ID: 18536556
[TBL] [Abstract][Full Text] [Related]
36. The multidisciplinary management of gastrointestinal cancer. The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer.
Van Cutsem E; Geboes K
Best Pract Res Clin Gastroenterol; 2007; 21(6):1089-108. PubMed ID: 18070705
[TBL] [Abstract][Full Text] [Related]
37. [Novel molecular approaches in the therapy of advanced colorectal carcinoma].
Vanhoefer U
Onkologie; 2003 Dec; 26 Suppl 7():70-4. PubMed ID: 14716146
[TBL] [Abstract][Full Text] [Related]
38. Managing patients with metastatic colorectal cancer on bevacizumab.
Lemmens L; Claes V; Uzzell M
Br J Nurs; 2008 Aug 14-Sep 10; 17(15):944-9. PubMed ID: 18983014
[TBL] [Abstract][Full Text] [Related]
39. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study.
Hochster HS; Hart LL; Ramanathan RK; Childs BH; Hainsworth JD; Cohn AL; Wong L; Fehrenbacher L; Abubakr Y; Saif MW; Schwartzberg L; Hedrick E
J Clin Oncol; 2008 Jul; 26(21):3523-9. PubMed ID: 18640933
[TBL] [Abstract][Full Text] [Related]
40. Clinical use of anti-vascular endothelial growth factor monoclonal antibodies in metastatic colorectal cancer.
Chase JL
Pharmacotherapy; 2008 Nov; 28(11 Pt 2):23S-30S. PubMed ID: 18980549
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
